Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed advanced and/or aggressive hematologic malignancy (including myelodysplastic syndrome) that is unlikely to be cured by alternative therapies~* HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor~* ECOG performance status 0-2~* Adequate organ function~* Able to understand and willing to sign a written informed consent document~* Agrees to practice adequate contraception per study requirements~Exclusion Criteria:~* Pregnant or breastfeeding~* Recipient of prior allogeneic or autologous stem cell transplantation~* Prior abdominal radiation therapy~* HIV-positive on combination antiretroviral therapy~* Seropositive for hepatitis B or C~* Allergies to bortezomib, boron, or mannitol~* Myocardial infarction within last 6 months, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias~* Uncontrolled bacterial, viral or fungal infections~* Seizures or history of seizures~* History of another non-hematologic malignancy unless disease-free for at least 5 years~* Uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Velcade/Tac/MTX (Type: EXPERIMENTAL): Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m\^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m\^2 IV

Based on this trial design, predict the completion outcome and termination type (if applicable).